Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 902

1.

Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.

Brjalin V, Salupere R, Tallo T, Kuznetsova T, Priimägi L, Tefanova V.

Cent Eur J Public Health. 2012 Jun;20(2):150-5.

PMID:
22966742
[PubMed - indexed for MEDLINE]
2.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
[PubMed - indexed for MEDLINE]
3.

[Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].

He LL, Chen Z, Chen Y, Xu H, Tang H, Lei BJ, Lei XZ.

Zhonghua Gan Zang Bing Za Zhi. 2011 Jan;19(1):34-7. doi: 10.3760/cma.j.issn.1007-3418.2011.01.010. Chinese.

PMID:
21272456
[PubMed - indexed for MEDLINE]
4.

Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.

Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V; PERICO Study Group.

J Infect Dis. 2012 Sep 15;206(6):961-8. Epub 2012 Jul 17.

PMID:
22807523
[PubMed - indexed for MEDLINE]
Free Article
5.

Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.

Urbanek P, Oltman M, Ivanovski L, Rehák V, Messinger D, Tietz A, Husa P.

Eur J Gastroenterol Hepatol. 2011 Nov;23(11):1004-10. doi: 10.1097/MEG.0b013e32834b326b.

PMID:
21904204
[PubMed - indexed for MEDLINE]
6.

Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment.

Yu JW, Sun LJ, Zhao YH, Kang P, Yan BZ.

Int J Infect Dis. 2011 Nov;15(11):e740-6. doi: 10.1016/j.ijid.2011.05.018. Epub 2011 Jul 30.

PMID:
21803628
[PubMed - indexed for MEDLINE]
Free Article
7.

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.

PMID:
18679072
[PubMed - indexed for MEDLINE]
8.

Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.

Aziz H, Raza A, Waheed Y, Gill U, Gill ML.

Int J Infect Dis. 2012 Aug;16(8):e597-602. doi: 10.1016/j.ijid.2012.03.012. Epub 2012 Jun 1.

PMID:
22658873
[PubMed - indexed for MEDLINE]
Free Article
9.

Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.

Hu CC, Lin CL, Kuo YL, Chien CH, Chen SW, Yen CL, Lin CY, Chien RN.

Aliment Pharmacol Ther. 2013 Jan;37(1):81-90. doi: 10.1111/apt.12112. Epub 2012 Nov 5.

PMID:
23121150
[PubMed - indexed for MEDLINE]
10.

Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.

Oze T, Hiramatsu N, Yakushijin T, Mochizuki K, Oshita M, Hagiwara H, Mita E, Ito T, Inui Y, Fukui H, Hijioka T, Katayama K, Tamura S, Yoshihara H, Inoue A, Imai Y, Hayashi E, Kato M, Hosui A, Miyagi T, Ishida H, Yoshida Y, Tatsumi T, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N.

J Gastroenterol. 2011 Aug;46(8):1031-7. doi: 10.1007/s00535-011-0409-7. Epub 2011 May 3.

PMID:
21538029
[PubMed - indexed for MEDLINE]
11.

Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.

Miyase S, Haraoka K, Ouchida Y, Morishita Y, Fujiyama S.

J Gastroenterol. 2012 Sep;47(9):1014-21. doi: 10.1007/s00535-012-0560-9. Epub 2012 Mar 2.

PMID:
22382633
[PubMed - indexed for MEDLINE]
12.
13.

Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4.

Al Ashgar H, Helmy A, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, Kagevi I, Alshehri A, Al Kalbani A, Al Swat K, Dahab S, Elkum N, Al Fadda M.

Ann Saudi Med. 2009 Jan-Feb;29(1):4-14.

PMID:
19139619
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Efficacy and factors influencing treatment with peginterferon alpha-2a and ribavirin in elderly patients with chronic hepatitis C.

Yu JW, Sun LJ, Kang P, Yan BZ, Zhao YH.

Hepatobiliary Pancreat Dis Int. 2012 Apr;11(2):185-92.

PMID:
22484588
[PubMed - indexed for MEDLINE]
Free Article
15.

Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.

Kuboki M, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

J Gastroenterol Hepatol. 2007 May;22(5):645-52. Erratum in: J Gastroenterol Hepatol. 2007 May;22(5):768.

PMID:
17444850
[PubMed - indexed for MEDLINE]
16.

Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.

Bonardi R, Tabone M, Manca A, Pellicano R, Ciancio A, Rizzetto M.

Biomed Pharmacother. 2011 Jul;65(4):303-6. doi: 10.1016/j.biopha.2011.03.004. Epub 2011 May 30.

PMID:
21723079
[PubMed - indexed for MEDLINE]
17.

Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.

Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study [KULDS] Group.

J Gastroenterol Hepatol. 2012 Jul;27(7):1233-40. doi: 10.1111/j.1440-1746.2011.06965.x.

PMID:
22098185
[PubMed - indexed for MEDLINE]
18.

[Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia].

Božić M, Bojović K, Fabri M, Nožić D, Trkulja B, Milošević I.

Srp Arh Celok Lek. 2012 Jul-Aug;140(7-8):448-55. Serbian.

PMID:
23092029
[PubMed - indexed for MEDLINE]
19.

[Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].

Husa P, Slesinger P, Stroblová H, Svobodník A, Husová L.

Klin Mikrobiol Infekc Lek. 2008 Apr;14(2):67-73. Czech.

PMID:
18756436
[PubMed - indexed for MEDLINE]
20.

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.

Rosen I, Kori M, Eshach Adiv O, Yerushalmi B, Zion N, Shaoul R.

World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098.

PMID:
23467199
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk